CLOS
ESPR

Compagnie Lombard Odier SCmA’s Esperion Therapeutics ESPR Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-700
Closed -$12K – 924
2016
Q1 		$12K Buy
700
+200
+40% +$3.22K ﹤0.01% 870
2015
Q4 		$11K Buy
+500
New +$12.6K ﹤0.01% 849

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ESPR Position: Q2 2016 in Review

Compagnie Lombard Odier SCmA sold out of Esperion Therapeutics (ESPR) in Q2 2016, closing a stake of 700 shares — an estimated $12K sold.

Compagnie Lombard Odier SCmA first reported a position in ESPR in Q4 2015 and held it in 2 quarters. The position peaked at $12K in Q1 2016. 102 funds tracked by Wall St. Rank hold ESPR as of Q2 2016.

  • Compagnie Lombard Odier SCmA reported no remaining Esperion Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 700 Esperion Therapeutics shares in Q2 2016, an estimated $12K.
  • Compagnie Lombard Odier SCmA first reported a position in Esperion Therapeutics in Q4 2015 and held it in 2 quarters.
  • Compagnie Lombard Odier SCmA's Esperion Therapeutics position peaked at $12K in Q1 2016.
  • 102 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2016.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2016, filed 15 Aug 2016.